
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is fundamentally attractive because its lead franchise keeps compounding: 3Q26 VYVGART sales reached about $1.72 billion, up 14% quarter over quarter and 53% year over year, with strong growth in both MG and CIDP, high access levels, and added convenience from the prefilled syringe. The company also shows meaningful pipeline depth, with ALKIVIA meeting its primary endpoint in autoimmune myositis, an IMNM sBLA expected by year-end, a Phase III celiac move for FB102, and multiple catalysts in 2026-27 that broaden the growth base beyond one product. Financially, 3Q26 net income was about $506 million on $1.751 billion of operating income, while $3.7 billion in cash and durable commercialization reduce funding risk and support continued investment.
Bears say
argenx is exposed to significant execution risk because Vyvgart’s growth may fall short, and expansion into oMG, ITP, myositis, and Sjogren’s could ultimately fail to convert into meaningful incremental revenue. Its valuation is also vulnerable to clinical, regulatory, or commercial setbacks for efgartigimod and ARGX-117, including unforeseen safety signals in ongoing trials, which could weaken confidence in the broader platform. Competition and macro headwinds such as FX, inflation, shipping risks, tariffs, and other R&D or regulatory disruptions further pressure the downside case and undermine long-term fundamental support.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About argenx (ARGX) Forecast
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares